Broad Institute Selects Applied Biosystems Capillary Electrophoresis DNA Analyzers for Ongoing Research.FOSTER CITY, Calif. -- Additional Suite of 3730xl DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. Analyzers Purchased to Support Range of Integrated Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. Genomics Projects Applied Biosystems Applied Biosystems, Inc. (formerly NASDAQ: ABIO) is the original name of a pioneer biotechnology company founded in 1981 in Foster City, California, among the Silicon Valley cities of the southern San Francisco Bay Area. Group (NYSE NYSE See: New York Stock Exchange :ABI Abi (ā`bī) [short for Abijah], in the Bible, King Hezekiah's mother. (Application Binary Interface) A specification for a specific hardware platform combined with the operating system. ), an Applera Corporation business, today announced the purchase and installation of a suite of new Applied Biosystems 3730xl DNA Analyzers by the Broad Institute of MIT MIT - Massachusetts Institute of Technology and Harvard. The new addition of 3730xl DNA Analyzers will increase the Institute's number of 3730xl DNA Analyzers by nearly 20 percent to a total of 126 instruments. The Broad Institute plans to use the 3730xl DNA Analyzers for a range of integrated genetic research studies, including de novo [Latin, Anew.] A second time; afresh. A trial or a hearing that is ordered by an appellate court that has reviewed the record of a hearing in a lower court and sent the matter back to the original court for a new trial, as if it had not been previously heard nor decided. sequencing of mammalian and other genomes and disease-related genotyping analyses. For more information about research projects underway at Broad Institute visit http://www.broad.mit.edu/. "The additional DNA analyzers complement our current installation of 3730xl DNA Analyzers. Capillary electrophoresis continues to be the robust foundation for our high-throughput production operations," said Eric Lander, Director, Broad Institute. "With the assistance of Applied Biosystems service and support teams, the new instruments were generating data in production in less than two days." "We are proud to be a long standing part of the Broad Institute's leading research programs in genome sequencing and medical sequencing, contributing to understanding genomes and exploring the genetic basis of disease," said Dennis A. Gilbert, Ph.D., Chief Scientific Officer of Applied Biosystems. "As one of the world's preeminent genome centers, Broad's choice of the 3730xl instruments is confirmation that capillary electrophoresis remains the gold standard in DNA analysis DNA analysis Any technique used to analyze genes and DNA. See Chromosome walking, DNA fingerprinting, Footprinting, In situ hybridization, Jeffries' probe, Jumping libraries, PCR, RFLP analysis, Southern blot hybridization. technology today." The Applied Biosystems 96-capillary 3730xl DNA Analyzer is the highest throughput system in the Applied Biosystems pioneering line of capillary electrophoresis instruments for DNA analysis. The production-scale system is specifically engineered to improve data quality, increase throughput, reduce project costs, and offer enhanced laboratory productivity. The system also offers flexibility, supporting a range of research projects including gene and genome sequencing, medical sequencing to discover causal mutations, genotyping, and genetic linkage analysis. Launched in 2002, the 3730 and 3730xl systems have rapidly become the industry's leading systems for large scale DNA sequencing, resequencing, and genotyping projects. Applied Biosystems continues to invest in the development and enhancement of capillary electrophoresis technology and the 3730 platform. About the Broad Institute The Broad Institute is known officially as The Eli and Edythe L. Broad Institute. It is a research collaboration of the Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, , Harvard University and its hospitals and the Whitehead Institute for Biomedical Research. The Broad mission is to create comprehensive tools for genomic medicine genomic medicine Molecular medicine The application of molecular methods to clinical medicine; MM encompasses diagnostic methods–eg, Southern, Western, and Northern blot hybridizations, DNA signal amplification by PCR, and use of agents produced by , make them freely available to scientists worldwide, and pioneer their application to understand and treat disease. About Applera Corporation and Applied Biosystems Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids Nucleic acids The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits. (DNA and RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic ), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2004. The Celera Genomics Group (NYSE:CRA See Community Reinvestment Act. ) is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune and inflammatory diseases. Celera Genomics is leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. It is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800-762-6923. Information about Applied Biosystems is available at www.appliedbiosystems.com. Applied Biosystems Forward Looking Statements Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "should" among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 provides a "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to (1) rapidly changing technology and dependence on the development and customer acceptance of new products; (2) sales dependent on customers' capital spending capital spending Spending for long-term assets such as factories, equipment, machinery, and buildings that permits the production of more goods and services in future years. policies and government-sponsored research; (3) Applied Biosystems' dependence on the operation of computer hardware, software, and Internet applications and related technology; (4) unproven use of genomics information to develop or commercialize products; and (5) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law. For Research Use Only. Not for use in diagnostic procedures. The Applied Biosystems 3730 and 3730xl DNA Analyzers include patented technology licensed from Hitachi, Ltd. as part of a strategic partnership between Applied Biosystems and Hitachi, Ltd., as well as patented technology of Applied Biosystems. Copyright(C) 2005. Applera Corporation. All rights reserved. Applied Biosystems and Celera are registered trademarks and Applera is a trademark of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion